RSVP today

All Rights Reserved. Forward ® 2019

EBD Group Inc.,  3150 Pio Pico Drive, Suite 201, Carlsbad, CA, 92008

The impact of AI: How AI and ML are transforming R&D, and what's next to come


When: Monday, January 13 at 4:00 pm
Where: Parc 55 – A Hilton Hotel, 4th Floor, Cyril Magnin Ballroom
What: Free access to the session and reception

FREE Monday Session 

January 13–15, 2020 
Parc 55 San Francisco – A Hilton Hotel,
San Francisco, CA

Artificial Intelligence is significantly influencing global healthcare including drug development. This discussion will highlight how AI, and specifically, machine learning, is being used to: identify novel therapeutics; find, characterize and intervene on behalf of patients; integrate Social Determinants of Health (SDOH) and other data to provide new insights into patient care; and ultimately enable companies to work more efficiently and effectively. The panel will also explore trends and implications in partnering, business models and capital formation that impact the innovation and adoption of AI in healthcare. 


Zavain Dar

Lux Capital

Ron Alfa

Senior VP, Translational Discovery and Chief Evangelist 
Recursion Pharmaceuticals


Rafael Rosengarten

CEO and Co-Founder
Genialis, Inc.

Chief Data and Analytics Officer
HVH Precision Analytics

Oodaye Shukla

Anastasia Christianson 

VP, R&D Operations and Oncology IT
Janssen Pharmaceutical Companies of Johnson & Johnson

Join us directly after for an Experience Zone Exhibits Reception
5:00 pm-6:00 pm 

Interact with companies whose technologies are changing the face of healthcare in the Experience Zone exhibits. Get hands on experience with digital medicine products such as therapeutics, assessment tools, diagnostics, wearable tech and AI/analytical tools. 

Sponsored by:

 US Pharma and Biotech Correspondent
Financial Times

Hannah Kuchler